A Guide to the Economics of Hepatitis C Virus Cure in 2017

about

A Guide to the Economics of Hepatitis C Virus Cure in 2017

Item

http://www.wikidata.org/entity/Q56654943

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@en

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@nl

type

Item

label

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@en

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@nl

prefLabel

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@en

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@nl

P1476

A Guide to the Economics of Hepatitis C Virus Cure in 2017

@en

P2093

Benjamin P Linas

http://www.w3.org/2001/XMLSchema#string

Shayla Nolen

http://www.w3.org/2001/XMLSchema#string

P2860

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States.

Cost Effectiveness and Cost Containment in the Era of Interferon-Free Therapies to Treat Hepatitis C Virus Genotype 1

Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection

Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

Thresholds for the cost-effectiveness of interventions: alternative approaches.

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States

P304

447-459

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IDC.2018.02.013

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin Linas

P577

2018-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29778265

http://www.w3.org/2001/XMLSchema#string

P932

6085105

http://www.w3.org/2001/XMLSchema#string